RECOMBINANT ADENOVIRUS COMPRISING HTERT MRNA TARGETING RIBOZYME AND P53 GENE
展开▼
机译:重组腺病毒,包含靶向mRNA的核糖核酸酶和P53基因
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to: a recombinant adenovirus; a host cell into which the recombinant adenovirus is introduced; a pharmaceutical composition comprising the recombinant adenovirus as an active ingredient for preventing or treating cancers; and a method for treating cancers comprising the step of administering the pharmaceutical composition including the recombinant adenovirus as an active ingredient to a subject in need of treatment at a pharmaceutically effective amount, wherein, the recombinant adenovirus comprises a promoter, a ribozyme which is targeted to human telomerase reverse transcriptase (hTERT) mRNA, and a p53 gene in an adenovirus backbone of which E1 and E3 are deleted. The recombinant adenovirus of the present invention inhibits the activity of hTERT mRNA, which is specifically overexpressed in cancer cells, by cutting hTERT mRNA through a trans-splicing ribozyme, and simultaneously allows p53, which is a therapeutic gene, to be expressed. Thus it is confirmed that cancer cells are effectively killed using the recombinant adenovirus of the present invention. Particularly, it is confirmed that liver tissue-specific migration, particularly selective motility toward cancer cells, is improved. Thus, since the recombinant adenovirus of the present invention does not show cell cytotoxicity to normal cells for systemic administration by having improved selective motility, the present invention can be used as a gene therapeutic agent for hepatoma cancer or metastatic liver cancer.
展开▼